ConductScience.org, home

Paper24253594

Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.

Dávila-Fajardo CL and 10 others. Pharmacogenet Genomics, 2014. Cited by 30 papers, by iCite.

Cite this record

ConductScience Library. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Papers, record 24253594. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24253594

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
PubMed
Journal
Pharmacogenet Genomics
PubMed
Year
2014
PubMed
Publication types
Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
30
iCite
Relative citation ratio, by iCite
1.07
iCite
Revised in PubMed
2022-03-10
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dávila-Fajardo CLCristina L
2Márquez AAna
3Pascual-Salcedo DDora
4Moreno Ramos MJManuel J
5García-Portales RRosa
6Magro CCésar
7Alegre-Sancho JJJuan J
8Balsa AAlejandro
9Cabeza-Barrera JJosé
10Raya EEnrique
11Martín JJavier

Source PubMed

Download CSV of authors

Topics25

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antirheumatic AgentsMajor topic
Arthritis, RheumatoidMajor topic
Immunoglobulin GMajor topic
Interleukin-6Major topic
Promoter Regions, GeneticMajor topic
Receptors, Tumor Necrosis FactorMajor topic
Tumor Necrosis Factor-alphaMajor topic
Adalimumab
Adult
Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cytosine
Etanercept
Female
Genetic Markers
Genotype
Guanine
Humans
Infliximab
Male
Middle Aged
Polymorphism, Single Nucleotide
Reproducibility of Results
Treatment Outcome

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02878161Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"Background

Source ClinicalTrials.gov

Download CSV of trials

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.

PMIDTitleJournalYearIn PapersSource
41892810Genomic Impacts of Biological Exposures.J Dev Biol2026https://conductscience.org/library/papers/41892810PubMed
37509625DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis.Biomedicines2023https://conductscience.org/library/papers/37509625PubMed
36013214Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis.J Pers Med2022https://conductscience.org/library/papers/36013214PubMed
36009355Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis.Biomedicines2022https://conductscience.org/library/papers/36009355PubMed
35238332Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search.Rheumatology (Oxford)2022https://conductscience.org/library/papers/35238332PubMed
35003068Toward Overcoming Treatment Failure in Rheumatoid Arthritis.Front Immunol2021https://conductscience.org/library/papers/35003068PubMed
33557301Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment.Cells2021https://conductscience.org/library/papers/33557301PubMed
33536774Relationship Between Interleukin-6 -174G/C Genetic Variant and Efficacy of Methotrexate Treatment in Psoriatic Arthritis Patients.Pharmgenomics Pers Med2021https://conductscience.org/library/papers/33536774PubMed
33047210IL6 genetic variants haplotype is associated with susceptibility and disease activity but not with therapy response in patients with inflammatory bowel disease.Int J Colorectal Dis2021https://conductscience.org/library/papers/33047210PubMed
32825059Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis.Biomolecules2020https://conductscience.org/library/papers/32825059PubMed
30283335Development of an AmpliSeqTM Panel for Next-Generation Sequencing of a Set of Genetic Predictors of Persisting Pain.Front Pharmacol2018https://conductscience.org/library/papers/30283335PubMed
30232372Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients.Sci Rep2018https://conductscience.org/library/papers/30232372PubMed
28607508Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.Pharmacogenomics J2017https://conductscience.org/library/papers/28607508PubMed
28600618Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis.Clin Rheumatol2018https://conductscience.org/library/papers/28600618PubMed
28356850Influence of Promoter Polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis.J Med Biochem2015https://conductscience.org/library/papers/28356850PubMed
27738630The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.Biomed Res Int2016https://conductscience.org/library/papers/27738630PubMed
26578807Genetic polymorphism directs IL-6 expression in fibroblasts but not selected other cell types.Proc Natl Acad Sci U S A2015https://conductscience.org/library/papers/26578807PubMed
26526676Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis.Clin Rheumatol2015https://conductscience.org/library/papers/26526676PubMed
26149736The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis.Pharmacogenomics J2016https://conductscience.org/library/papers/26149736PubMed
25990005Predictors of response to TNF-α antagonist therapy in Chinese rheumatoid arthritis.Clin Rheumatol2015https://conductscience.org/library/papers/25990005PubMed

See all 21 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IL63569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24253594

GET https://conductscience.org/api/papers/v1/24253594/cited_by?page=2